eXoZymes, Inc.

NASDAQ:EXOZ

Biotechnology

Healthcare
$5.54 +16.75%

+$1.06 today

Market cap
$51.42M
Beta
2.66
P/E (TTM)
-6.5
EPS (TTM)
-$1.14
52W Low $6.33High $18.40

Volume 0.01M

Average 0.01M

EXOZ Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

eXoZymes, Inc.NASDAQ: EXOZ

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $1.19M fell 13.4% year over year, behind the +24.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 24.7% from the prior quarter. Over 3 fiscal years it compounded at +91.9% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -13.4% toward the trailing-twelve-month pace of +24.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.19M-24.7% QoQ
Last fiscal yearDec 2025
$5.91M+55.8% YoY
LTMMar 2026
$5.71M+24.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.4%——
1 year+55.8%——
3-year CAGR+91.9%——
5-year CAGR——
10-year CAGR——

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
5.91M USD
Year-over-year change
+55.8%
4-year CAGR
+66.0%

Selling, General & Admin vs competitors

How EXOZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +24.9% is the 2nd highest of 7, against a peer median of -3.6%.
  • Over three fiscal years its annual growth of +91.9% compares with a peer median of +3.0%.
EXOZ Competitors
Selling, General & Admin for EXOZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TILInstil Bio, Inc.LTM Mar 2026$23.46M USD-41.6%-24.1%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$18.6M CAD+58.0%+35.4%—
SRZNSurrozen, Inc.LTM Mar 2026$18.36M USD+21.1%-6.5%244.9%
TLSATiziana Life Sciences LtdFY2025$10.77M USD+4.7%+31.3%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$10.32M USD-12.0%-7.1%—
EXOZeXoZymes, Inc.LTM Mar 2026$5.71M USD+24.9%+91.9%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$2.36M USD-26.5%+12.5%—
Peer median (excluding EXOZ) —-3.6%+3.0%244.9%

Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue59.41K147.75K0267.38K0
Gross Profit(59.41K)(147.75K)0(267.38K)0
Gross Margin—————
Research & Development454.45K348.08K527.48K1.87M3.71M
Selling, General & Admin778.99K836.83K1.34M3.8M5.91M
Operating Expenses1.23M1.18M1.8M5.66M9.72M
Depreciation & Amortization59.41K147.75K196.94K267.38K287.96K
EBITDA(1.15M)(1.18M)(1.8M)(5.59M)(8.98M)
EBITDA Margin—————
Operating Income(1.29M)(1.33M)(1.8M)(5.93M)(9.72M)
Operating Margin—————
Interest Income09810077.61K0
Interest Expense00000
Other Income / Expenses83.74K98(199.9K)70.77K452.53K
Income Before Tax(1.21M)(1.33M)(2M)(5.86M)(9.26M)
Pre-Tax Margin—————
Income Tax Expense063.56K42.27K0(105.21K)
Net Income(1.21M)(1.4M)(2.04M)(5.86M)(9.16M)
Net Margin—————
EPS (Basic)(0.15)(0.17)(0.25)(0.72)(1.09)
EPS (Diluted)(0.15)(0.17)(0.25)(0.72)(1.09)
Weighted Avg Shares8.13M8.13M8.13M8.13M8.38M
Weighted Avg Shares (Diluted)8.13M8.13M8.13M8.13M8.38M

eXoZymes, Inc.

NASDAQ:EXOZ

Intrinsic Alpha fair value

Locked

Current Price

$5.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.